TanCAR-T cell agents can be used as an effective treatment strategy to regulate tumor development, but the detection of limitations for therapeutic use seems to be necessary.34 Clinical trials of tyrosine kinase HER2 inhibitors are progressing as low levels of HER2 are successfully identified in some cancers by Herceptin. This evidence concerns the gene ERBB2 and neoplasm.